Output details

Recombinant Complement Receptor 2 Radiolabeled with [Tc-99m(CO)(3)](+): A Potential New Radiopharmaceutical for Imaging Activated Complement

This paper identifies a new molecular target for molecular imaging of inflammation: activated complement, and describes the first radiopharmaceutical, 99mTc-recombinant complement receptor 2, for so doing. It is intended for non-invasively assessing the severity of tissue injury post myocardial infarction (MI) or solid organ transplantations (SOT) soon after ischaemia reperfusion injury (IRI), for which no imaging techniques currently exist. It led to a current British Heart Foundation grant evaluating the radiopharmaceutical in preclinical models of MI and SOT with a view to translating into man, which would enabling clinicians to risk-stratify patients as well as monitor therapeutic interventions.